Gastrointestinal Hematology Oncology Research concentrates on clinical and
translational research to find new and more personalized treatment for
areas of GI, Hepatobiliary and Pancreatic Cancers. The physicians
collaborate with research scientists of the Cancer Center at BIDMC to
advance our knowledge of the genomics and pathogeneses of these cancers and
to bring cutting-edge treatments to our patients.
The Gastrointestinal Hematology Oncology Research program
physicians/researchers include Drs. Andrea Bullock and Susan Pandya. Supporting their clinical research are
Adrianna Cortez, Clinical Research Associate and Meagan Lynch, Research
Dr. Buchbinder's translational research focuses on Hepatobiliary cellular
cancer. In collaboration with the scientists of the cancer research
program, she is working to understand the mechanisms involved in the PI3K
pathways. She has created a tissue bank as a clinical data base to develop
better personalized treatment protocols.
Dr. Bullock's clinical research areas of interest include Pancreatic and
Colorectal cancers and translational research in pancreatic cancer to
understand the pathogenesis of the disease and develop new treatments with
BRCA as a target. She is also involved is Health Services research that
most recently has examined the economics of cancer care from the patient's
perspective and the role of the physician.
Dr. Pandya's clinical interests include pancreatic and colon cancers. She
is the overall Principal Investigator for a multi-center international
Phase II clinical trial in pancreatic cancer. She is the associated
director of the experimental therapeutics program at BIDMC which offers
novel targeted drugs for clinical testing.
S. S. Pandya, J. W. Mier, D. F. McDermott, D. C. Cho. Addition of
gemcitabine at time of sunitinib resistance in metastatic renal cell
cancer. British Journal of Urology International 2011. doi: 10.1111/j.1464-410X.2011.10096.x. [Epub ahead of print]
J. R. Diamond, B. R. Bastos, R. J. Hansen, D. L. Gustafson, S. G. Eckhardt,
E. L. Kwak, S. S. Pandya, G. C. Fletcher, T. M. Pitts, G. N. Kulikowski, M.
Morrow, J. Arnott, M. R. Bray, C. Sidor, W. Messersmith, G. I. Shapiro.
Phase I safety, pharmacokinetic and pharmacodynamic study of ENMD-2076, a
novel angiogenic and aurora kinase inhibitor, in patients with advanced
solid tumors. Clinical Cancer Research. 2011;17:849-860.
D. B. Costa, S. Kobayashi, S. S. Pandya, W. Yeo, Z. Shen, W. Tan, and K. D.
Wilner. CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor
Crizotinib. Journal of Clinical Oncology 2011 29:e443-e445.
A. J. Bullock, E.J. Hofstatter, M.L. Yushak, M. K. Buss. Understanding
Patients' Attitudes Toward Communication About the Cost of Cancer Care.
Journal of Oncology Practice. Epub Feb 28, 2011 Abstract: http://ascopubs.org/doi/full/10.1200/jop.2011.000418
A. Mahadevan, R. Miksad, M. Goldstein, R. Sullivan, A. J. Bullock, E.
Buchbinder, D. Pleskow, M. Sawhney, T. Kent, C. Vollmer, M. Callery.
Induction gemcitabine and stereotactic body radiotherapy for locally
advanced nonmetastatic pancreas cancer. International Journal of Radiation
Oncology • Biology • Physics. 2011 Nov 15;81(4). Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21658854